CA3099776A1 - Quinazoline derivatives as antitumor agents - Google Patents

Quinazoline derivatives as antitumor agents Download PDF

Info

Publication number
CA3099776A1
CA3099776A1 CA3099776A CA3099776A CA3099776A1 CA 3099776 A1 CA3099776 A1 CA 3099776A1 CA 3099776 A CA3099776 A CA 3099776A CA 3099776 A CA3099776 A CA 3099776A CA 3099776 A1 CA3099776 A1 CA 3099776A1
Authority
CA
Canada
Prior art keywords
yloxy
triazolo
pyrimidin
amine
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099776A
Other languages
English (en)
French (fr)
Inventor
Ding Zhou
Ziqiang CHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Suzhou Zanrong Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zanrong Pharma Ltd filed Critical Suzhou Zanrong Pharma Ltd
Publication of CA3099776A1 publication Critical patent/CA3099776A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3099776A 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents Pending CA3099776A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018106098 2018-09-18
CNPCT/CN2018/106098 2018-09-18
CNPCT/CN2019/091078 2019-06-13
CN2019091078 2019-06-13
PCT/CN2019/106233 WO2020057511A1 (en) 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
CA3099776A1 true CA3099776A1 (en) 2020-03-26

Family

ID=69888359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099776A Pending CA3099776A1 (en) 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents

Country Status (19)

Country Link
US (2) US11723908B2 (cg-RX-API-DMAC7.html)
EP (3) EP4360713B1 (cg-RX-API-DMAC7.html)
JP (3) JP7546550B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250171398A (cg-RX-API-DMAC7.html)
CN (2) CN112654612A (cg-RX-API-DMAC7.html)
AU (4) AU2019341273B2 (cg-RX-API-DMAC7.html)
CA (1) CA3099776A1 (cg-RX-API-DMAC7.html)
DK (2) DK3853220T3 (cg-RX-API-DMAC7.html)
ES (2) ES2971927T3 (cg-RX-API-DMAC7.html)
FI (2) FI4360713T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20240293T1 (cg-RX-API-DMAC7.html)
HU (2) HUE069764T2 (cg-RX-API-DMAC7.html)
LT (2) LT4360713T (cg-RX-API-DMAC7.html)
PL (2) PL4360713T3 (cg-RX-API-DMAC7.html)
PT (2) PT4360713T (cg-RX-API-DMAC7.html)
RS (2) RS65413B1 (cg-RX-API-DMAC7.html)
SI (2) SI4360713T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400524T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020057511A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚(上海)生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN110357858B (zh) 2018-04-09 2022-02-18 威尚(上海)生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva
CN111377850B (zh) * 2018-12-31 2022-10-18 艾琪康医药科技(上海)有限公司 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
WO2021209039A1 (zh) * 2020-04-17 2021-10-21 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2突變抑制劑
JP7598180B2 (ja) * 2021-03-19 2024-12-11 北京賽特明強医薬科技有限公司 キナゾリン系化合物、キナゾリン系化合物の組成物及び応用
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN117940424A (zh) * 2021-06-22 2024-04-26 缆图药品公司 Egfr抑制剂
WO2022271749A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
US20240382483A1 (en) * 2021-06-22 2024-11-21 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN117836286A (zh) 2021-06-22 2024-04-05 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
CN115894455B (zh) * 2021-09-30 2024-04-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
CN115894383B (zh) * 2021-09-30 2025-12-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
CR20240163A (es) * 2021-10-20 2024-06-12 Hoffmann La Roche Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas
CN116478129B (zh) * 2022-01-21 2025-01-07 深圳默元生物科技有限公司 喹啉化合物及其用途
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
US20250206760A1 (en) * 2022-03-28 2025-06-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲(江蘇)醫藥股份有限公司 喹唑啉ErbB抑制劑的藥物形式
WO2024249642A1 (en) * 2023-06-02 2024-12-05 Acerand Therapeutics (Hong Kong) Limited Egfr inhibitors
EP4786473A1 (en) * 2023-09-27 2026-08-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof
TW202602446A (zh) 2024-03-19 2026-01-16 瑞士商豪夫邁 羅氏有限公司 Erbb2抑制劑的藥物製劑

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
CN1437594A (zh) 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
RU2004116911A (ru) * 2001-11-03 2005-11-10 Астразенека Аб (Se) Производные хиназолина в качестве противоопухолевых средств
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2004000529A1 (de) 2002-06-24 2003-12-31 Fagerdala Deutschland Gmbh Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
KR20090090336A (ko) * 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
CN115057861A (zh) * 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
EP3516071B1 (en) * 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
CN109422755B (zh) 2017-09-01 2023-07-04 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
CN111630046B (zh) * 2017-12-19 2023-01-10 成都金瑞基业生物科技有限公司 喹唑啉衍生物及其应用
WO2019214651A1 (zh) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
TWI811358B (zh) 2018-05-08 2023-08-11 大陸商迪哲(江蘇)醫藥股份有限公司 ErbB受體抑制劑
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva

Also Published As

Publication number Publication date
JP2024164018A (ja) 2024-11-26
FI4360713T3 (fi) 2024-12-27
JP7546550B2 (ja) 2024-09-06
AU2026205380A1 (en) 2026-07-23
CN112654612A (zh) 2021-04-13
ES2971927T3 (es) 2024-06-10
ES3007082T3 (en) 2025-03-19
EP4360713A2 (en) 2024-05-01
AU2024204847A1 (en) 2024-08-01
HRP20240293T1 (hr) 2024-05-24
PL3853220T3 (pl) 2024-09-02
SMT202400524T1 (it) 2025-01-14
US11723908B2 (en) 2023-08-15
KR20210061329A (ko) 2021-05-27
EP3853220A4 (en) 2022-06-22
EP4360713B1 (en) 2024-10-30
PT3853220T (pt) 2024-02-22
RS66314B1 (sr) 2025-01-31
LT4360713T (lt) 2025-01-10
AU2019341273A1 (en) 2020-11-19
PL4360713T3 (pl) 2025-06-23
HUE069764T2 (hu) 2025-04-28
AU2026206192A1 (en) 2026-08-06
US20210386742A1 (en) 2021-12-16
JP2022501338A (ja) 2022-01-06
PT4360713T (pt) 2025-01-07
RS65413B1 (sr) 2024-05-31
SI4360713T1 (sl) 2025-02-28
DK3853220T3 (da) 2024-03-04
WO2020057511A1 (en) 2020-03-26
DK4360713T3 (da) 2025-01-06
HUE065578T2 (hu) 2024-06-28
KR102889933B1 (ko) 2025-11-24
JP2026009898A (ja) 2026-01-21
LT3853220T (lt) 2024-03-12
EP4523755A2 (en) 2025-03-19
EP4360713A3 (en) 2024-05-22
HRP20241743T1 (hr) 2025-02-28
SI3853220T1 (sl) 2024-04-30
EP3853220B1 (en) 2024-01-03
FI3853220T3 (fi) 2024-02-22
US20230293533A1 (en) 2023-09-21
KR20250171398A (ko) 2025-12-08
EP4523755A3 (en) 2025-06-11
CN118255772A (zh) 2024-06-28
AU2019341273B2 (en) 2024-09-26
EP3853220A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
AU2019341273B2 (en) Quinazoline derivatives as antitumor agents
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
JP7706585B2 (ja) 毛細血管拡張性運動失調症変異(ATM)キナーゼの選択的調節物質としての1-イソプロピル-3-メチル-8-(ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オンおよびその使用
BRPI0618668A2 (pt) composto, composição, método pra o tratamento de uma doença hiperproliferativa em um mamìfero, uso de um composto e método para a preparação de um composto
AU2025203211A1 (en) ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
CN120265635A (zh) 抗癌核激素受体靶向化合物
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
HK40108721A (en) Quinazoline derivatives as antitumor agents
TW202545531A (zh) 氮—喹唑啉化合物之使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240215

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250716

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250821

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260325